Expression of vasohibin‑1 and ‑2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus

  • Authors:
    • Yamato Ninomiya
    • Soji Ozawa
    • Junya Oguma
    • Akihito Kazuno
    • Miho Nitta
    • Hiroshi Kajiwara
    • Yasufumi Sato
  • View Affiliations

  • Published online on: August 1, 2018     https://doi.org/10.3892/ol.2018.9249
  • Pages: 5265-5274
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vasohibin (VASH) ‑1 and ‑2 are novel angiogenic regulators. The aim of the present study was to assess the prognostic values of VASH1 expression and VASH2 expression in esophageal squamous cell carcinoma (ESCC). A total of 209 patients with ESCC were investigated. Resected tumor specimens were immunostained using anti‑CD34 antibody, anti‑VASH1 antibody and anti‑VASH2 antibody. The ratio of the microvessels density and the VASH1 density as the VASH1‑positive ratio were defined and the patients were divided into two groups (a high VASH1 group and a low VASH1 group) according to the average value. The patients were also divided into two groups (a high VASH2 group and a low VASH2 group) according to VASH2 expression upon immunostaining. The clinical outcomes of these two groups were then evaluated. The high VASH1 group contained 106 patients (50.7%). The high VASH2 group contained 48 patients (23.0%). Long‑term survival was significantly poorer in the high VASH1 group compared with that in the low VASH1 group. A slight correlation between VASH1 expression and VASH2 expression was observed. The low VASH1/low VASH2 group had a better prognosis than the other three groups with different combinations of VASH1 and VASH2 expression levels. The present study showed that high VASH1 expression and high VASH2 expression may be novel independent predictors of a poor prognosis in patients with ESCC and that a slight correlation between VASH1 and VASH2 expression existed. The present findings suggest that combined evaluation of VASH1 and VASH2 expression should provide an improved understanding of their clinicopathological features.
View Figures
View References

Related Articles

Journal Cover

October-2018
Volume 16 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ninomiya Y, Ozawa S, Oguma J, Kazuno A, Nitta M, Kajiwara H and Sato Y: Expression of vasohibin‑1 and ‑2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus. Oncol Lett 16: 5265-5274, 2018
APA
Ninomiya, Y., Ozawa, S., Oguma, J., Kazuno, A., Nitta, M., Kajiwara, H., & Sato, Y. (2018). Expression of vasohibin‑1 and ‑2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus. Oncology Letters, 16, 5265-5274. https://doi.org/10.3892/ol.2018.9249
MLA
Ninomiya, Y., Ozawa, S., Oguma, J., Kazuno, A., Nitta, M., Kajiwara, H., Sato, Y."Expression of vasohibin‑1 and ‑2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus". Oncology Letters 16.4 (2018): 5265-5274.
Chicago
Ninomiya, Y., Ozawa, S., Oguma, J., Kazuno, A., Nitta, M., Kajiwara, H., Sato, Y."Expression of vasohibin‑1 and ‑2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus". Oncology Letters 16, no. 4 (2018): 5265-5274. https://doi.org/10.3892/ol.2018.9249